The role of vaccines in the COVID-19 pandemic: what have we learned?

7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection

(2023) Ulrika Marking et al.   LANCET INFECTIOUS DISEASES

Design of a pan-betacoronavirus vaccine candidate through a phylogenetically informed approach

(2023) Eric Lewitus et al.   Science Advances

Generation of a high yield vaccine backbone for influenza B virus in embryonated chicken eggs

(2023) Sadaf Aslam et al.   npj Vaccines

SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron

(2022) Alison Tarke et al.   CELL

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021

(2022) Matthew E. Oster et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity

(2022) Bo Meng et al.   NATURE

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

(2022) Juan Manuel Carreño et al.   NATURE

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

(2022) Sandile Cele et al.   NATURE

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

(2022) Peter B. Gilbert et al.   SCIENCE

The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis

(2022) Marharyta Sobczak et al.   Clinical and Molecular Allergy

COVAX and equitable access to COVID-19 vaccines

(2022) Katelyn Yoo et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

(2022) Philip C. Mack et al.   CANCER CELL

Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada

(2022) Danuta M Skowronski et al.   CLINICAL INFECTIOUS DISEASES

COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022

(2022) Jonas Björk et al.   Eurosurveillance

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection

(2022) Salma Sheikh-Mohamed et al.   Mucosal Immunology

Defining the risk of SARS-CoV-2 variants on immune protection

(2022) Marciela M. DeGrace et al.   NATURE

Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

(2022) Karen J. Hager et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

(2022) Juliet R. C. Pulliam et al.   SCIENCE

Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models

(2022) Lena Mautner et al.   Virology Journal

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

(2022) Hiam Chemaitelly et al.   Nature Communications

Thrombotic Complications after COVID-19 Vaccination: Diagnosis and Treatment Options

(2022) Katharina Guetl et al.   Biomedicines

Guillain–Barré syndrome following influenza vaccination: A 15‐year nationwide population‐based case–control study

(2022) Lotte Sahin Levison et al.   EUROPEAN JOURNAL OF NEUROLOGY

Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis

(2022) Natalina Sutton et al.   Expert Review of Vaccines

Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS‐CoV ‐2 infection*

(2022) Salma Sheikh‐Mohamed et al.   IMMUNOLOGICAL REVIEWS

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial

(2022) Gary A Herman et al.   LANCET INFECTIOUS DISEASES

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5

(2022) Qian Wang et al.   NATURE

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models

(2022) Alexander A. Cohen et al.   SCIENCE

SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies

(2022) Kevin W. Ng et al.   Science Translational Medicine

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

(2022) María Eugenia-Toledo-Romaní et al.   VACCINE

Infections with the SARS-CoV-2 Delta variant exhibit fourfold increased viral loads in the upper airways compared to Alpha or non-variants of concern

(2022) Christian J. H. von Wintersdorff et al.   Scientific Reports

Pulmonary resident memory T cells in respiratory virus infection and their inspiration on therapeutic strategies

(2022) Meng Zhang et al.   Frontiers in Immunology

Nucleocapsid as a next-generation COVID-19 vaccine candidate

(2022) Bryan Oronsky et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults

(2022) Rajeka Lazarus et al.   JOURNAL OF INFECTION

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

(2022) Rajeka Lazarus et al.   LANCET INFECTIOUS DISEASES

Protection against Omicron from Vaccination and Previous Infection in a Prison System

(2022) Elizabeth T. Chin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection

(2022) Sebastian Havervall et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern

(2022) Mijia Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations

(2022) Juan Manuel Carreño et al.   VACCINE

SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals

(2022) Kaori Sano et al.   Nature Communications

Wastewater Testing and Detection of Poliovirus Type 2 Genetically Linked to Virus Isolated from a Paralytic Polio Case — New York, March 9–October 11, 2022

(2022) A. Blythe Ryerson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials

(2022) Subhash Thuluva et al.   EBioMedicine

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

(2022) Meera Madhavan et al.   EBioMedicine

Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes

(2022) Sarah A. Buchan et al.   JAMA Network Open

Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains

(2022) Yu Wu et al.   JAMA Network Open

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy

(2022) Ilana Katz Sand et al.   Multiple Sclerosis and Related Disorders

Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022

(2022) Hannah G. Rosenblum et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

(2021) Raches Ella et al.   LANCET INFECTIOUS DISEASES

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

(2021) Denis Y Logunov et al.   LANCET

Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein

(2021) Houriiyah Tegally et al.   NATURE

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2

(2021) Kimberly G. Blumenthal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model

(2021) Fatima Amanat et al.   mBio

Defining the root cause of reduced H1N1 live attenuated influenza vaccine effectiveness: low viral fitness leads to inter-strain competition

(2021) Oliver Dibben et al.   npj Vaccines

The evolutionary history of ACE2 usage within the coronavirus subgenus Sarbecovirus

(2021) H L Wells et al.   Virus Evolution

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

(2021) Paul A Kristiansen et al.   LANCET

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

(2021) Brian J. Ward et al.   NATURE MEDICINE

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

(2021) Oliver Van Oekelen et al.   CANCER CELL

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

(2021) Fatima Amanat et al.   CELL

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults

(2021) Nawal Al Kaabi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Work Absence Following COVID-19 Vaccination in a Cohort of Healthcare Personnel

(2021) Laura E. Breeher et al.   JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

(2021) Mine Durusu Tanriover et al.   LANCET

Broad sarbecovirus neutralization by a human monoclonal antibody

(2021) M. Alejandra Tortorici et al.   NATURE

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors

(2021) Chee-Wah Tan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

(2021) Paul T. Heath et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

(2021) Hana M. El Sahly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hybrid immunity

(2021) Shane Crotty   SCIENCE

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

(2021) David R. Martinez et al.   SCIENCE

Broad betacoronavirus neutralization by a stem helix–specific human antibody

(2021) Dora Pinto et al.   SCIENCE

Evidence for antibody as a protective correlate for COVID-19 vaccines

(2021) Kristen A. Earle et al.   VACCINE

Immunological imprinting of the antibody response in COVID-19 patients

(2021) Teresa Aydillo et al.   Nature Communications

Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave

(2021) Matthew M. Hernandez et al.   Nature Communications

Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects

(2021) Madeleine F. Jennewein et al.   Cell Reports

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021

(2021) Catherine M. Brown et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

The “anti-vax” movement: a quantitative report on vaccine beliefs and knowledge across social media

(2021) Staci L Benoit et al.   BMC PUBLIC HEALTH

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

(2021) Adolfo Aleman et al.   CANCER CELL

Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Recovery of Infectious Virus Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals

(2021) Chun Huai Luo et al.   CLINICAL INFECTIOUS DISEASES

Comparative safety of mRNA COVID‐19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database

(2021) Min Seo Kim et al.   JOURNAL OF MEDICAL VIROLOGY

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

(2021) Scott A Halperin et al.   LANCET

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

(2021) Raches Ella et al.   LANCET

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

(2021) Noam Barda et al.   LANCET

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines

(2021) Ai-ris Y. Collier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Covid-19 Vaccine Effectiveness in New York State

(2021) Eli S. Rosenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 spike engagement of ACE2 primes S2′ site cleavage and fusion initiation

(2021) Shi Yu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Towards a population-based threshold of protection for COVID-19 vaccines

(2021) David Goldblatt et al.   VACCINE

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses

(2021) Weina Sun et al.   Nature Communications

The early phase of the COVID-19 epidemic in Lombardy, Italy

(2021) Danilo Cereda et al.   Epidemics

Stabilized coronavirus spike stem elicits a broadly protective antibody

(2021) Ching-Lin Hsieh et al.   Cell Reports

Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies

(2021) Magdalena M. Żak et al.   Heliyon

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

(2021) Peter G Kremsner et al.   LANCET INFECTIOUS DISEASES

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

(2020) Michael Letko et al.   Nature Microbiology

SARS-CoV-2 Vaccines: Status Report

(2020) Fatima Amanat et al.   IMMUNITY

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

(2020) Ching-Lin Hsieh et al.   SCIENCE

Distinct conformational states of SARS-CoV-2 spike protein

(2020) Yongfei Cai et al.   SCIENCE

The COVID-19 Pandemic and the $16 Trillion Virus

(2020) David M. Cutler et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

SARS-CoV-2 vaccines in development

(2020) Florian Krammer   NATURE

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cryptic transmission of SARS-CoV-2 in Washington state

(2020) Trevor Bedford et al.   SCIENCE

The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET

(2020) Chuang Liu et al.   STRUCTURE

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Correlates of protection against SARS-CoV-2 in rhesus macaques

(2020) Katherine McMahan et al.   NATURE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced SARS-CoV-2 neutralization by dimeric IgA

(2020) Zijun Wang et al.   Science Translational Medicine

IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody

(2019) Shinji Saito et al.   PLoS Pathogens

The how’s and what’s of vaccine reactogenicity

(2019) Caroline Hervé et al.   npj Vaccines

Narcolepsy Associated with Pandemrix Vaccine

(2018) Tomi Sarkanen et al.   Current Neurology and Neuroscience Reports

HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure

(2018) Peter D. Kwong et al.   IMMUNITY

mRNA vaccines — a new era in vaccinology

(2018) Norbert Pardi et al.   NATURE REVIEWS DRUG DISCOVERY

Strategies to induce broadly protective antibody responses to viral glycoproteins

(2017) F Krammer   Expert Review of Vaccines

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

(2017) Jesper Pallesen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pre-fusion structure of a human coronavirus spike protein

(2016) Robert N. Kirchdoerfer et al.   NATURE

Development of high-yield influenza B virus vaccine viruses

(2016) Jihui Ping et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Induction of mucosal immunity through systemic immunization: Phantom or reality?

(2016) Fei Su et al.   Human Vaccines & Immunotherapeutics

Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs

(2015) Callie Ridenour et al.   Influenza and Other Respiratory Viruses

A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence

(2015) Vineet D Menachery et al.   NATURE MEDICINE

Serious adverse events associated with yellow fever vaccine

(2015) Reinaldo de Menezes Martins et al.   Human Vaccines & Immunotherapeutics

Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevent cross-linked multimer formation and potency loss

(2014) Kathleen M Holtz et al.   BMC BIOTECHNOLOGY

Nomenclature for Immune Correlates of Protection After Vaccination

(2012) S. A. Plotkin et al.   CLINICAL INFECTIOUS DISEASES

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

(2012) Ali M. Zaki et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of Homing Receptors on IgA1 and IgA2 Plasmablasts in Blood Reflects Differential Distribution of IgA1 and IgA2 in Various Body Fluids

(2010) S. H. Pakkanen et al.   Clinical and Vaccine Immunology

Correlates of Protection Induced by Vaccination

(2010) S. A. Plotkin   Clinical and Vaccine Immunology